Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Thrombotic accidents induced by thalidomide: two cases].

J Gachon1, J J Grob, M A Richard

  • 1Service de dermatologie, hôpital Sainte-Marguerite, CHU, 270, boulevard de Sainte-Marguerite, 13274 Marseille, France.

La Revue De Medecine Interne
|October 4, 2002
PubMed
Summary

Thalidomide reintroduction for autoimmune and neoplastic diseases is linked to severe thrombotic events. Pre-treatment coagulation screening is recommended to mitigate risks associated with this potent drug.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of Tinea Capitis in children under 10 kg : Results from a French multicentre study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Out-of-pocket expenses of hidradenitis suppurativa: A cross-sectional study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Evaluation of stigmatization in patients with hidradenitis suppurativa using the PUSH-D score.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Diagnostic wandering in hidradenitis suppurativa: A nationwide cohort study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024

Area of Science:

  • Pharmacology
  • Hematology
  • Oncology

Background:

  • Thalidomide, initially withdrawn due to teratogenicity, is now used for autoimmune and neoplastic diseases.
  • Neuropathies are known side effects, with recent reports linking thalidomide to thrombotic events.

Observation:

  • Two cases of severe venous thrombosis (deep-vein thrombosis and pulmonary embolism) occurred during thalidomide treatment.
  • One patient experienced recurrent thrombosis despite anticoagulation, resolving only after thalidomide cessation.
  • Thrombotic events typically manifest within three months of initiating thalidomide therapy.

Findings:

  • Thalidomide may act as a precipitating or initiating factor for thrombosis in at-risk patients.
  • The precise mechanism underlying thalidomide-induced thrombosis remains unknown.

Related Experiment Videos

  • These thrombotic complications associated with thalidomide can be severe.

    • Implications:

    • A comprehensive coagulation assessment before thalidomide initiation is crucial.
    • Increased vigilance for thrombotic events is necessary in patients receiving thalidomide.
    • Further research into the pro-thrombotic mechanisms of thalidomide is warranted.